{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T10:51:47Z","timestamp":1793184707489,"version":"4.5.0"},"reference-count":35,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T00:00:00Z","timestamp":1768089600000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005230","name":"Chongqing Natural Science Foundation","doi-asserted-by":"publisher","award":["CSTB2024NSCQ-MSX1114"],"award-info":[{"award-number":["CSTB2024NSCQ-MSX1114"]}],"id":[{"id":"10.13039\/501100005230","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100014869","name":"Chongqing Xinqiao Hospital, Second Affiliated Hospital of Army Medical University","doi-asserted-by":"publisher","award":["2024F030"],"award-info":[{"award-number":["2024F030"]}],"id":[{"id":"10.13039\/501100014869","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017501","name":"Science Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","award":["2023QNXM045"],"award-info":[{"award-number":["2023QNXM045"]}],"id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017501","name":"Science Health Joint Medical Scientific Research Project of Chongqing","doi-asserted-by":"publisher","award":["2024GGXM001"],"award-info":[{"award-number":["2024GGXM001"]}],"id":[{"id":"10.13039\/100017501","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101108","type":"journal-article","created":{"date-parts":[[2026,1,11]],"date-time":"2026-01-11T22:48:53Z","timestamp":1768171733000},"page":"101108","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score\u2013matched analysis"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7122-8606","authenticated-orcid":false,"given":"Wen","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhou","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuemei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongfan","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5184-0777","authenticated-orcid":false,"given":"Guansong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"14","key":"10.1016\/j.ctarc.2026.101108_bib0002","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.3390\/jcm13144189","article-title":"Advances in non-small cell lung cancer: current insights and future directions","volume":"13","author":"Garg","year":"2024","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ctarc.2026.101108_bib0003","first-page":"1","article-title":"Optimizing response to gefitinib in the treatment of non-small-cell lung cancer","volume":"4","author":"Carotenuto","year":"2011","journal-title":"Pharmacogenomics Pers. Med."},{"key":"10.1016\/j.ctarc.2026.101108_bib0004","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.616546","article-title":"An updated network meta-analysis of EGFR-TKIs and combination therapy in the first-line treatment of advanced EGFR mutation positive non-small cell lung cancer","volume":"12","author":"Qi","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0005","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1186\/s12890-024-03336-8","article-title":"Optimal first-line treatment for EGFR-mutated NSCLC: a comparative analysis of osimertinib and second-generation EGFR-TKIs","volume":"24","author":"Chen","year":"2024","journal-title":"BMC. Pulm. Med."},{"issue":"11","key":"10.1016\/j.ctarc.2026.101108_bib0006","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3390\/cancers13112748","article-title":"EGFR in cancer: signaling mechanisms, drugs, and acquired resistance","volume":"13","author":"Uribe","year":"2021","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0007","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1186\/s12890-023-02472-x","article-title":"Efficacy and safety of EGFR-TKIs in combination with angiogenesis inhibitors as first-line therapy for advanced EGFR-mutant non-small-cell lung cancer: a systematic review and meta-analysis","volume":"23","author":"Hu","year":"2023","journal-title":"BMC. Pulm. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101108_bib0008","first-page":"7589","article-title":"Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors","volume":"14","author":"Taniguchi","year":"2017","journal-title":"Oncol. Lett."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0009","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1186\/s12890-025-03569-1","article-title":"Prognostic factors influencing overall survival in stage IV EGFR-mutant NSCLC patients treated with EGFR-TKIs","volume":"25","author":"Kuang","year":"2025","journal-title":"BMC. Pulm. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101108_bib0010","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.21037\/tlcr-21-206","article-title":"Different prognostic implications of hepatic metastasis according to front-line treatment in non-small cell lung cancer: a real-world retrospective study","volume":"10","author":"Choi","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101108_bib0011","first-page":"7589","article-title":"Impact of metastatic status on the prognosis of EGFR mutation-positive non-small cell lung cancer patients treated with first-generation EGFR-tyrosine kinase inhibitors","volume":"14","author":"Taniguchi","year":"2017","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ctarc.2026.101108_bib0012","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241275421","article-title":"Molecular features of NSCLC patients with liver metastasis","volume":"16","author":"Zhao","year":"2024","journal-title":"Ther. Adv. Med. Oncol."},{"issue":"12","key":"10.1016\/j.ctarc.2026.101108_bib0013","doi-asserted-by":"crossref","first-page":"13431","DOI":"10.3390\/cimb46120801","article-title":"Long-term outcomes in patients with EGFR positive lung adenocarcinoma and subgroup analysis based on presence of liver metastases","volume":"46","author":"V","year":"2024","journal-title":"Curr. Issues. Mol. Biol."},{"key":"10.1016\/j.ctarc.2026.101108_bib0014","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1186\/s12967-015-0622-x","article-title":"Impact of epidermal growth factor receptor (EGFR) activating mutations and their targeted treatment in the prognosis of stage IV non-small cell lung cancer (NSCLC) patients harboring liver metastasis","volume":"13","author":"Casta\u00f1\u00f3n","year":"2015","journal-title":"J. Transl. Med."},{"issue":"6","key":"10.1016\/j.ctarc.2026.101108_bib0015","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.cllc.2017.04.015","article-title":"Characterization of liver metastasis and its effect on targeted therapy in EGFR-mutant NSCLC: a multicenter study","volume":"18","author":"Jiang","year":"2017","journal-title":"Clin. Lung Cancer"},{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0016","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1038\/s41598-024-83930-2","article-title":"Presence of liver metastasis correlated with high tumor abundance and indicated adverse prognostic feature in EGFR mutation non-small-cell lung cancer patients","volume":"15","author":"Sitthideatphaiboon","year":"2025","journal-title":"Sci. Rep."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0017","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12885-022-09741-8","article-title":"Clinical efficacy of osimertinib in EGFR-mutant non-small cell lung cancer with distant metastasis","volume":"22","author":"Gen","year":"2022","journal-title":"BMC. Cancer"},{"issue":"2","key":"10.1016\/j.ctarc.2026.101108_bib0018","first-page":"228","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur. J. Cancer Oxf. Engl.1990"},{"key":"10.1016\/j.ctarc.2026.101108_bib0019","article-title":"Common terminology criteria for adverse events (CTCAE) version 5.0. Myeloma UK","year":"2025","journal-title":"Accessed"},{"issue":"12","key":"10.1016\/j.ctarc.2026.101108_bib0020","doi-asserted-by":"crossref","first-page":"13443","DOI":"10.3390\/cimb46120802","article-title":"Treatment options for patients with non-small cell lung cancer and liver metastases","volume":"46","author":"\u0106eriman Krsti\u0107","year":"2024","journal-title":"Curr. Issues. Mol. Biol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101108_bib0021","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1056\/NEJMoa1713137","article-title":"Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer","volume":"378","author":"Soria","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101108_bib0022","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s40264-017-0596-0","article-title":"Erlotinib plus bevacizumab phase ll study in patients with advanced non-small-cell lung cancer (JO25567): updated safety results","volume":"41","author":"Kato","year":"2018","journal-title":"Drug Saf."},{"issue":"7","key":"10.1016\/j.ctarc.2026.101108_bib0023","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1093\/jjco\/hyad052","article-title":"Current treatment strategies for EGFR-mutated non-small cell lung cancer: from first line to beyond osimertinib resistance","volume":"53","author":"Araki","year":"2023","journal-title":"Jpn. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ctarc.2026.101108_bib0024","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1200\/JCO.19.01488","article-title":"Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study","volume":"38","author":"Hosomi","year":"2020","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"31","key":"10.1016\/j.ctarc.2026.101108_bib0025","doi-asserted-by":"crossref","first-page":"3587","DOI":"10.1200\/JCO.21.02911","article-title":"Updated analysis of NEJ009: gefitinib-alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated EGFR","volume":"40","author":"Miyauchi","year":"2022","journal-title":"J. Clin. Oncol. J. Am. Soc. Clin. Oncol."},{"issue":"21","key":"10.1016\/j.ctarc.2026.101108_bib0026","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1056\/NEJMoa2306434","article-title":"Osimertinib with or without chemotherapy in EGFR-mutated advanced NSCLC","volume":"389","author":"Planchard","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2026.101108_bib0027","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1186\/s12885-021-08291-9","article-title":"Efficacy and acquired resistance of EGFR-TKI combined with chemotherapy as first-line treatment for Chinese patients with advanced non-small cell lung cancer in a real-world setting","volume":"21","author":"Wang","year":"2021","journal-title":"BMC. Cancer"},{"key":"10.1016\/j.ctarc.2026.101108_bib0028","article-title":"Third-generation egfr-tkis combined with chemotherapy in advanced non-small cell lung cancer: a real-world study","author":"Jiang","year":"2025","journal-title":"Cancer Sci."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101108_bib0029","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2024.2362889","article-title":"First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials","volume":"24","author":"Landre","year":"2024","journal-title":"Expert. Rev. AntiCancer Ther."},{"issue":"8","key":"10.1016\/j.ctarc.2026.101108_bib0030","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1080\/14737140.2024.2362889","article-title":"First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trials","volume":"24","author":"Landre","year":"2024","journal-title":"Expert. Rev. AntiCancer Ther."},{"key":"10.1016\/j.ctarc.2026.101108_bib0031","article-title":"Efficacy of EGFR-TKI plus chemotherapy or monotherapy as first-line treatment for advanced EGFR-mutant lung adenocarcinoma patients with co-mutations","volume":"11","author":"Yang","year":"2021","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0032","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1186\/s12890-024-03438-3","article-title":"What is the optimal first-line regimen for advanced non-small cell lung cancer patients with epidermal growth factor receptor mutation: a systematic review and network meta-analysis","volume":"24","author":"Zhang","year":"2024","journal-title":"BMC. Pulm. Med."},{"key":"10.1016\/j.ctarc.2026.101108_bib0033","first-page":"1","article-title":"EGFR-TKI plus chemotherapy versus TKI monotherapy in advanced EGFR-mutant NSCLC with high PD-L1 expression: a real-world retrospective study","volume":"21","author":"Su","year":"2025","journal-title":"Expert. Rev. AntiCancer Ther."},{"issue":"1","key":"10.1016\/j.ctarc.2026.101108_bib0034","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1186\/s12885-022-10391-z","article-title":"Efficacy and safety analyses of epidermal growth factor receptor tyrosine kinase inhibitors combined with chemotherapy in the treatment of advanced non\u2013small-cell lung cancer with an EGFR\/TP53 co-mutation","volume":"22","author":"Shang","year":"2022","journal-title":"BMC. Cancer"},{"issue":"4","key":"10.1016\/j.ctarc.2026.101108_bib0035","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1007\/s11523-024-01073-w","article-title":"Adverse event profile of epidermal growth factor receptor tyrosine kinase inhibitors for non-small cell lung cancer: an updated meta-analysis","volume":"19","author":"Zhou","year":"2024","journal-title":"Target. Oncol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T00:22:11Z","timestamp":1773966131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":35,"alternative-id":["S2468294226000171"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101108","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of first-line EGFR-TKI combined with chemotherapy versus EGFR-TKI monotherapy in patients with EGFR-mutant non-small cell lung cancer and liver metastases: A propensity score\u2013matched analysis","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101108","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101108"}}